Signos Announces $20M Series B Funding


In a move to address the pressing challenges posed by obesity and metabolic health in the United States, Signos, the comprehensive metabolic health platform based in San Francisco, has secured a significant $20 million in Series B funding. This announcement was made on October 24, 2023. The infusion of capital is set to empower Signos to take significant steps in its mission to combat the ongoing crisis.

Leading this crucial funding round are Cheyenne Ventures and GV (Google Ventures), with additional support coming from Dexcom Ventures and Samsung Next. This collective backing emphasizes the importance of Signos’ vision in a time when metabolic health issues, including prediabetes and diabetes, continue to escalate.

The scale of the problem is daunting, with more than 96 million Americans classified as prediabetic, and projections that diabetes may affect over 1 billion people by 2050. In response, Signos is already making a significant impact through its innovative approach. It revolves around early detection and lifestyle modifications, offering a metabolic-led solution to reverse prediabetes and aid those embarking on their weight loss journeys.

What sets Signos apart is its proprietary AI-engine, which works in harmony with a continuous glucose monitor (CGM) to provide real-time data and tailored recommendations for healthy weight management. While initially designed for non-diabetics, Signos expanded its weight management platform in May 2023 to cater to people living with Type 2 diabetes, broadening its scope of support.

At the heart of Signos’ approach is its user-friendly app. Members can meticulously log their dietary choices and exercise routines. This data feeds into the Signos AI platform, allowing it to learn and analyze how an individual’s metabolism reacts to various foods and fitness patterns. The result is a highly personalized set of data-driven recommendations tailored to each user’s unique metabolic profile.

This remarkable funding milestone positions Signos at the forefront of metabolic health solutions, offering a beacon of hope and innovation in the face of a growing crisis. As the company expands its core team and platform, it’s poised to make a significant impact on the lives of those grappling with metabolic health challenges across the nation.

This announcement received media coverage from prominent outlets including CNBC, Fortune, FinSMEs, Jumpstart, newsletters like Axios, and our press release gained traction on Yahoo Finance.